U.S. equities were higher, with the S&P 500 up 0.4% on Wednesday following further indications from the Federal Reserve that policymakers may be more cautious about raising interest rates to bring down inflation. On Thursday, the Labor Department is set to release the closely watched September report on consumer prices.

Much of Wednesday's market-moving action surrounded the 澳洲幸运5官方开奖结果体彩网:announcement by Novo Nordisk (NVO) that it had wrapped up earlier than expected on 🅷a study of its injectable diabete𝄹s and weight-loss drug Ozempic to treat kidney disease because it likely was successful.

That news contributed to Novo Nordisk's 澳洲幸运5官方开奖结果ꦉ体彩网:American Depositary Receipts (ADRs) lifting 6% and helped send dialysis machine and insulin pump makers' stocks plunging. Shares of DaVita (DVA), Baxter International (BAX), Insulet (PODD), and DexCom (DXCM) lost 16.8%, 12.3%, 8.7%,ဣ and 7.3%, respectively.

Catalent (CTLT) shares jumped 5.5% after anticipation that the Ozempic decision would boost demand for the firm's syringes. Eli Lilly (LLY) shares also gained 4.5% on the day, w🦹ith optimism that the Ozempic news will increase sales of its Mounjaro diabetes ꩲtreatment.

Amgen (AMGN) shares added 4.5% following an upgrade from Leerink Partners, which s💝aid that the biotech company's stock should move hi꧙gher because of the firm's accelerating pipeline.

Walgreens Boots Alliance (WBA) shares added 1% as the biggest U.S. pharmacy chain announced that former Cigna (CI) executive Tim Wentworth would take over as its ne𝔉w CEO.

Pioneer Natural Resources (PXD) shares rose 1.5% after Exxon Mobil (XOM) agreed to 澳洲幸运5官方开奖结果体彩网:buy the shale oil driller for $59.5 billion. Exxon Mobil sha💞res dropped 3.6%.